Cytek Biosciences (CTKB) Common Equity (2020 - 2026)

Cytek Biosciences' Common Equity history runs 7 years deep, the most recent figure standing at $327.6 million for Q1 2026.

• Quarterly Common Equity fell 13.69% year-over-year to $327.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $327.6 million (down 13.69% YoY) and the FY2025 annual result came in at $341.7 million, down 13.64% from the prior year.
• Common Equity was $327.6 million for Q1 2026 at Cytek Biosciences, down from $341.7 million in the prior quarter.
• Across five years, Common Equity topped out at $425.5 million in Q4 2022 and bottomed at $327.6 million in Q1 2026.
• A 5-year average of $393.2 million and a median of $393.1 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity jumped 40644.2% — and 2026, when it slipped 13.69%.
• Cytek Biosciences' Common Equity stood at $425.5 million in 2022, then dropped by 7.63% to $393.1 million in 2023, then rose by 0.68% to $395.7 million in 2024, then fell by 13.64% to $341.7 million in 2025, then decreased by 4.12% to $327.6 million in 2026.
• Business Quant data shows CTKB's Common Equity at $327.6 million in Q1 2026, $341.7 million in Q4 2025, and $378.6 million in Q3 2025.